Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme

L.H. van der Helm, C. Alhan, P.W. Wijermans, M.V. Kooy, R. Schaafsma, B.J. Biemond, A. Beeker, M. Hoogendoorn, B.P. van Rees, O. de Weerdt, J. Wegman, W.J. Libourel, SA Luykx-de Bakker, M.C. Minnema, R.E. Brouwer, F.C.D. Boer, M. Eefting, K.S.G. Jie, A.A. van de Loosdrecht, J. KoedamN.J.G.M. Veeger, E. Vellenga, G. Huls

Research output: Contribution to journalArticleAcademicpeer-review

Original languageUndefined/Unknown
Pages (from-to)599-606
JournalBritish Journal of Haematology
Issue number5
Publication statusPublished - 2011

Cite this